Please use this identifier to cite or link to this item:
https://doi.org/10.21256/zhaw-3446| Publication type: | Conference poster |
| Type of review: | Not specified |
| Title: | The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland |
| Authors: | Rüthemann, Isabelle Auerbach, Holger |
| DOI: | 10.21256/zhaw-3446 |
| Conference details: | Versorgungsforschung in der Schweiz: das Beispiel Onkologie, Bern, 1. November 2012 |
| Issue Date: | 2012 |
| Publisher / Ed. Institution: | Schweizerische Akademie der Medizinischen Wissenschaften |
| Publisher / Ed. Institution: | Bern |
| Language: | English |
| Subject (DDC): | 615: Pharmacology and therapeutics |
| Abstract: | In Switzerland, every year about 5’500 women are diagnosed with breast cancer and 1’500 people with non-Hodgkin's lymphoma. The targeted therapy with MabThera® is the standard of care for many patients with Non-Hodgkin’s lymphoma, whereas Herceptin® is approved for the treatment of a certain type of breast cancer. Currently both drugs are administered intravenously (IV), yet a subcutaneous application (SC) is in development. Assuming the same price for the future subcutaneous formulation, this study compared the cost and revenue situation of both application forms. The analysis was performed both in hospital outpatient- and resident oncologists-settings in Switzerland. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/13926 |
| Fulltext version: | Published version |
| License (according to publishing contract): | Licence according to publishing contract |
| Departement: | School of Management and Law |
| Organisational Unit: | Winterthur Institute of Health Economics (WIG) |
| Appears in collections: | Publikationen School of Management and Law |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 203409.pdf | 1.78 MB | Adobe PDF |  View/Open |
Show full item record
Rüthemann, I., & Auerbach, H. (2012). The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland. Versorgungsforschung in Der Schweiz: Das Beispiel Onkologie, Bern, 1. November 2012. https://doi.org/10.21256/zhaw-3446
Rüthemann, I. and Auerbach, H. (2012) ‘The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland’, in Versorgungsforschung in der Schweiz: das Beispiel Onkologie, Bern, 1. November 2012. Bern: Schweizerische Akademie der Medizinischen Wissenschaften. Available at: https://doi.org/10.21256/zhaw-3446.
I. Rüthemann and H. Auerbach, “The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland,” in Versorgungsforschung in der Schweiz: das Beispiel Onkologie, Bern, 1. November 2012, 2012. doi: 10.21256/zhaw-3446.
RÜTHEMANN, Isabelle und Holger AUERBACH, 2012. The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland. In: Versorgungsforschung in der Schweiz: das Beispiel Onkologie, Bern, 1. November 2012. Conference poster. Bern: Schweizerische Akademie der Medizinischen Wissenschaften. 2012
Rüthemann, Isabelle, and Holger Auerbach. 2012. “The Cost and Revenue Situation of Intravenous Administration versus Subcutaneous Application of Herceptin and MabThera in Switzerland.” Conference poster. In Versorgungsforschung in Der Schweiz: Das Beispiel Onkologie, Bern, 1. November 2012. Bern: Schweizerische Akademie der Medizinischen Wissenschaften. https://doi.org/10.21256/zhaw-3446.
Rüthemann, Isabelle, and Holger Auerbach. “The Cost and Revenue Situation of Intravenous Administration versus Subcutaneous Application of Herceptin and MabThera in Switzerland.” Versorgungsforschung in Der Schweiz: Das Beispiel Onkologie, Bern, 1. November 2012, Schweizerische Akademie der Medizinischen Wissenschaften, 2012, https://doi.org/10.21256/zhaw-3446.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.